Literature DB >> 29553995

OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FINDINGS IN A CASE OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO TRAUMATIC CHOROIDAL RUPTURE.

Chiara Preziosa1, Federico Corvi1, Marco Pellegrini1, Sara Bochicchio1, Ana P Rosar1,2, Giovanni Staurenghi1.   

Abstract

BACKGROUND/
PURPOSE: To document by optical coherence tomography angiography, the onset of a choroidal neovascularization (CNV) secondary to traumatic choroidal rupture and describe its changes after an intravitreal injection of bevacizumab.
METHODS: Case report.
RESULTS: A 20-year-old woman presented referring vision loss after a blunt ocular trauma in her left eye. The patient underwent a complete ophthalmic examination. Best-corrected visual acuity was 20/200. Fundus examination, fluorescein angiography, indocyanine green angiography, and optical coherence tomography displayed a choroidal rupture with no evidence of CNV. Optical coherence tomography angiography showed the choroidal rupture as a line of choriocapillaris rarefaction because of the mechanical damage. Six months later, best-corrected visual acuity decreased to 20/300; optical coherence tomography angiography displayed the growth of a CNV, characterized by a tangled vascular network. After one intravitreal injection of bevacizumab, optical coherence tomography angiography documented a contraction of the CNV.
CONCLUSION: Optical coherence tomography angiography is a useful imaging technique for the diagnosis and follow-up of patients with choroidal ruptures. Anti-vascular endothelial growth factor agents represent an effective therapy for the treatment of CNVs secondary to this affection.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 29553995     DOI: 10.1097/ICB.0000000000000704

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  1 in total

1.  A reappraisal of indirect choroidal rupture using swept-source optical coherence tomography in-vivo pathology images in patients with blunt eye trauma.

Authors:  Anupriya Arthur; Nancy Magdalene Rajasekaran; Thomas Kuriakose
Journal:  Indian J Ophthalmol       Date:  2020-10       Impact factor: 1.848

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.